Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

Abstract Poster

Authors

null

Ursula A. Matulonis

Dana-Farber Cancer Institute, Boston, MA

Ursula A. Matulonis , Jorn Herrstedt , Anna Tinker , Frederik Marme , Andres Redondo , Elsa Kalbacher , Jonathan A. Ledermann , Joanna Pikiel , Rene dePont Christensen , Jonathan S. Berek , Trine Juhler-Nøttrup , Amit M. Oza , Werner Meier , Marta Gil-Martin , Anne-Claire Hardy-Bessard , Bradley J. Monk , Per Rosenberg , Robert Michael Wenham , Sebastien Hazard , Mansoor Raza Mirza

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01847274

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5534)

DOI

10.1200/JCO.2017.35.15_suppl.5534

Abstract #

5534

Poster Bd #

356

Abstract Disclosures

Similar Posters

First Author: Mansoor Raza Mirza

First Author: Jose Maria Del Campo

First Author: JUNG-YUN LEE

First Author: Elena Ioana Braicu